ERBB2 and breast carcinoma: Therefore, this study investigated the role of BCSCs in HER2 subtype conversion, the radioresistance of HER2-negative breast cancer cells, and analyzed whether serum HER2 could be a clinical biomarker for the evaluation of HER2 subtype conversion from advanced HER2-negative breast cancer.